NCT02981069

Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in Type 2 Diabetes Mellitus (T2DM)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 90 (actual)
• Sponsor: The University of Texas Health Science Center at San Antonio · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

In this study, the researchers hope to learn about SGLT2 inhibition on EGP (endogenous glucose production) and plasma glucose concentration in diabetic subjects. Researchers will examine diabetes and the role of increased plasma glucagon, decline in plasma insulin, and fall in plasma glucose concentration.

Detailed description

This study will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose concentration compared to each agent alone.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	Dapagliflozin	10mg
DRUG	Exenatide	Byetta 5 to 10 ug (twice daily) Bydureon 2mg (once weekly)
DRUG	Placebo	Placebo for Dapagliflozin

Timeline

• Start date: 2017-12-15
• Primary completion: 2022-07-14
• Completion: 2023-03-19
• First posted: 2016-12-02
• Last updated: 2023-07-20
• Results posted: 2023-07-20

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study